Statin-induced myopathy: a review and update

Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients

(2013) David J. Becker   ANNALS OF INTERNAL MEDICINE

Narrative Review: Statin-Related Myopathy

(2013) Tisha R. Joy   ANNALS OF INTERNAL MEDICINE

Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia

(2012) Terry A. Jacobson   MAYO CLINIC PROCEEDINGS

Evidence-Based Management of Statin Myopathy

(2010) Charles R. Harper et al.   Current Atherosclerosis Reports

Statin myopathy: a review of recent progress

(2010) Andrew L Mammen et al.   CURRENT OPINION IN RHEUMATOLOGY

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy

(2010) Yiannis S. Chatzizisis et al.   DRUG SAFETY

The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients

(2010) L.E. Degreef et al.   European Journal of Internal Medicine

Approach to the Patient Who Is Intolerant of Statin Therapy

(2010) Robert H. Eckel   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Tolerability of Red Yeast Rice (2,400 mg Twice Daily) Versus Pravastatin (20 mg Twice Daily) in Patients With Previous Statin Intolerance

(2009) Steven C. Halbert et al.   AMERICAN JOURNAL OF CARDIOLOGY

The genetics of statin-induced myopathy

(2009) Abhijit Ghatak et al.   ATHEROSCLEROSIS

Association between statin-associated myopathy and skeletal muscle damage

(2009) M. G. Mohaupt et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Transporter Pharmacogenetics and Statin Toxicity

(2009) M Niemi   CLINICAL PHARMACOLOGY & THERAPEUTICS

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

(2009) Kornelia Kotseva et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

(2009) Deepak Voora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Myopathy with statin–fibrate combination therapy: clinical considerations

(2009) Terry A. Jacobson   Nature Reviews Endocrinology

Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction

(2008) Zongliang Lu et al.   AMERICAN JOURNAL OF CARDIOLOGY

Coenzyme Q10 Depletion: Etiopathogenic or Predisposing Factor in Statin Associated Myopathy?

(2008) Yiannis S. Chatzizisis et al.   AMERICAN JOURNAL OF CARDIOLOGY

Efficacy of Rosuvastatin (5 mg and 10 mg) Twice a Week in Patients Intolerant to Daily Statins

(2008) Mamatha Gadarla et al.   AMERICAN JOURNAL OF CARDIOLOGY

Safety of Niacin and Simvastatin Combination Therapy

(2008) Harold Bays   AMERICAN JOURNAL OF CARDIOLOGY

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.

(2008) Scott E. Conard et al.   AMERICAN JOURNAL OF CARDIOLOGY

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease

(2008) Lawrence A. Leiter et al.   AMERICAN JOURNAL OF CARDIOLOGY

Once-a-Week Rosuvastatin (2.5 to 20 mg) in Patients With a Previous Statin Intolerance

(2008) Janelle F. Ruisinger et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance

(2008) James M Backes et al.   ANNALS OF PHARMACOTHERAPY

Molecular basis of statin-associated myopathy

(2008) Christos Vaklavas et al.   ATHEROSCLEROSIS

Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques

(2008) Yiannis S. Chatzizisis et al.   ATHEROSCLEROSIS

Antiretroviral and Statin Drug-Drug Interactions

(2008) Gretchen M. Ray   Cardiology in Review

Managing Dyslipidemia in Chronic Kidney Disease

(2008) Charles R. Harper et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low serum 25 (OH) vitamin D levels (

(2008) Waqas Ahmed et al.   Translational Research

Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins

(2007) Evan A. Stein et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients

(2007) Vasilios G. Athyros et al.   AMERICAN JOURNAL OF CARDIOLOGY